- Home
- GH vs ORLA Comparison
GH vs ORLA Comparison
Compare GH & ORLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GH | ORLA |
|---|---|---|
| Founded | 2011 | 2007 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 3.9B |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | GH | ORLA |
|---|---|---|
| Price | $103.60 | $13.91 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 21 | 1 |
| Target Price | ★ $79.19 | $27.00 |
| AVG Volume (30 Days) | ★ 2.9M | 1.9M |
| Earning Date | 10-29-2025 | 11-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 2239.45 |
| EPS | N/A | ★ 0.16 |
| Revenue | ★ $902,569,000.00 | $772,153,000.00 |
| Revenue This Year | $34.72 | $183.80 |
| Revenue Next Year | $26.46 | $36.88 |
| P/E Ratio | ★ N/A | $87.57 |
| Revenue Growth | 30.38 | ★ 145.83 |
| 52 Week Low | $29.91 | $4.72 |
| 52 Week High | $112.43 | $14.36 |
Technical Indicators
Market Signals| Indicator | GH | ORLA |
|---|---|---|
| Relative Strength Index (RSI) | 66.40 | 68.50 |
| Support Level | $98.23 | $11.50 |
| Resistance Level | $112.43 | $14.36 |
| Average True Range (ATR) | 5.44 | 0.72 |
| MACD | -0.54 | 0.26 |
| Stochastic Oscillator | 64.46 | 89.05 |
Price Performance
Historical ComparisonAbout GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
About ORLA Orla Mining Ltd.
Orla Mining Ltd is a mineral exploration company. It is engaged in the acquisition and exploration of mineral properties. The company holds three gold projects; the Camino Rojo gold and silver project in Zacatecas State, Musselwhite gold mine project located in Ontario and the South Railroad projects in Nevada, USA, and the Cerro Quema gold project in Panama. It conducts business activities in Mexico, Panama, the United States, and Canada.